17 related articles for article (PubMed ID: 37172427)
1. FATP2 regulates Osteoclastogenesis by increasing lipid metabolism and ROS production.
Kong X; Tao S; Ji Z; Li J; Li H; Jin J; Zhao Y; Liu J; Zhao F; Chen J; Feng Z; Chen B; Shan Z
J Bone Miner Res; 2024 Mar; ():. PubMed ID: 38477781
[TBL] [Abstract][Full Text] [Related]
2. ACSL1-Mediated Fatty Acid β-Oxidation Enhances Metastasis and Proliferation in Endometrial Cancer.
Zhou Y; Li Y; Chen G; Guo X; Gao X; Meng J; Xu Y; Zhou N; Zhang B; Zhou X
Front Biosci (Landmark Ed); 2024 Feb; 29(2):66. PubMed ID: 38420815
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of Nrf2 accelerates renal lipid deposition through suppressing the ACSL1 expression in obesity-related nephropathy.
Chen Y; He L; Yang Y; Chen Y; Song Y; Lu X; Liang Y
Ren Fail; 2019 Nov; 41(1):821-831. PubMed ID: 31488013
[No Abstract] [Full Text] [Related]
4. MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA.
Cui M; Wang Y; Sun B; Xiao Z; Ye L; Zhang X
Biochem Biophys Res Commun; 2014 Feb; 444(2):270-5. PubMed ID: 24462768
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of CD36 and acyl-CoA synthetases FATP2, FATP4 and ACSL1 increases fatty acid uptake in human hepatoma cells.
Krammer J; Digel M; Ehehalt F; Stremmel W; Füllekrug J; Ehehalt R
Int J Med Sci; 2011; 8(7):599-614. PubMed ID: 22022213
[TBL] [Abstract][Full Text] [Related]
6. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
7. FATP2 regulates non-small cell lung cancer by mediating lipid metabolism through ACSL1.
Chen Y; Zhao Y; Deng Y; Yang Y; Xu L; Fu J
Tissue Cell; 2023 Jun; 82():102105. PubMed ID: 37172427
[TBL] [Abstract][Full Text] [Related]
8. FATP2-targeted therapies - A role beyond fatty liver disease.
Qiu P; Wang H; Zhang M; Zhang M; Peng R; Zhao Q; Liu J
Pharmacol Res; 2020 Nov; 161():105228. PubMed ID: 33027714
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
